|N04BA03 - Levodopa, Decarboxylase Inhibitor and Comt Inhibitor||ATC-DDD Version 2016. Source: WHO|
|N04 - Anti-Parkinson Drugs|
This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.
The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.
No separate DDDs are established for oral depot formulations.
|N04B - Dopaminergic Agents|
|N04BA - Dopa and Dopa Derivatives|
Combinations with decarboxylase inhibitors and other dopaminergic agents are classified here.
The DDD for the combination of levodopa and decarboxylase inhibitor is based on the content of levodopa, see ATC index.
|N04BA03 - Levodopa, Decarboxylase Inhibitor and Comt Inhibitor|
|0.45 g||O||Refers to levodopa|